Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Multiple Myeloma 4Lymphoma 4Hodgkin Disease 4Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Leukemia 3Hematologic Neoplasms 3Vomiting 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Kidney Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomatitis 1Stomach Neoplasms 1

Interventions

Cyclophosphamide 118Peripheral Blood Stem Cell Transplantation 67Filgrastim 60Etoposide 60Rituximab 54fludarabine phosphate 50Vincristine 46Radiotherapy 46Methotrexate 46Cytarabine 44Doxorubicin 40Cyclosporine 35Mycophenolic Acid 33Busulfan 33Prednisone 32Whole-Body Irradiation 31Tacrolimus 28Antilymphocyte Serum 28Melphalan 27Dexamethasone 26Methylprednisolone 22Leucovorin 19Carmustine 18Granulocyte Colony-Stimulating Factor 17Calcium Dobesilate 16Ifosfamide 15Psychiatric Rehabilitation 13Cord Blood Stem Cell Transplantation 13sargramostim 12merphos 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Burkitt Lymphoma × Diphenhydramine × Clear all
NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡